Oxidative stress and damage in liver, but not in brain, of Fischer 344 rats subjected to dietary iron supplementation with lipid-soluble [(3,5,5-trimethylhexanoyl)ferrocene]

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 3, 2007, Pages 145-155

  Lykkesfeldt, Jens ^a   Morgan, Evan ^b   Christen, Stephan ^c   Skovgaard, Lene Theil ^a   Moos, Torben ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antioxidant; Ferritin; Glutathione; Hemeoxygenase; Malondialdehyde

Indexed keywords

3 NITROTYROSINE; ALPHA TOCOPHEROL; DICIFERRON; FERRITIN; FERROCENE DERIVATIVE; GAMMA TOCOPHEROL; GLUTATHIONE; HEME OXYGENASE 1; IRON; MALONALDEHYDE; UNCLASSIFIED DRUG;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN PROTECTION; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FISCHER 344 RAT; IRON THERAPY; KUPFFER CELL; LIVER CELL; LIVER INJURY; LIVER LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; RISK FACTOR;

ANIMAL FEED; ANIMALS; BRAIN; DIETARY SUPPLEMENTS; FERROUS COMPOUNDS; IRON; LIPIDS; LIVER; OXIDATIVE STRESS; RATS; RATS, INBRED F344; SOLUBILITY;

RATTUS;

EID: 34447512982     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20170     Document Type: Article

References (39)

1. Focht SJ, Snyder BS, Beard JL, Van Gelder W, Williams LR, Connor JR. Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Neuroscience 1997;79:255-261.
2. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol Biol 2000;46:731-741.
3. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-873.
4. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006;13:142-148.
5. Benkovic SA, Connor JR. Ferritin, transferrin, and iron in selected regions of the young and aged rat brain. J Comp Neurol 1993;338:97-113.
6. Bartzokis G, Mintz J, Sultzer D, Marx P, Herzberg JS, Phelan CK, Marder SR. In vivo MR evaluation of age-related increases in brain iron. Am J Neuroradiol 1994;15:1129-1138.
7. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999;17:213-222.
8. Floor E. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease. Cell Mol Biol 2000;46:709-720.
9. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: Relation to iron content. Radiology 1999;211:489-495.
10. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 2006;10:223-253.
11. Russo N, Edwards M, Andrews T, O'Brien M, Bhatia KP. Hereditary haemochromatosis is unlikely to cause movement disorders - a critical review. J Neurol 2004;251:849-852.
12. Moos T, Trinder D, Morgan EH. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and β2-microglobulin deficient mouse brain. Cell Mol Biol 2000;46:549-561.
13. 54Mn in mouse brain. J Neurol Sci 1999;170:112-118.
14. Zheng W, Aschner M, Ghersi-Egea JF. Brain barrier systems: A new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003;192:1-11.
15. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, Dolan KG, Haile DJ, Beard JL, Connor JR. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 2001;66:1198-1207.
16. Crossgrove JS, Yokel RA. Manganese distribution across the blood-brain barrier III. The divalent metal transporter-1 is not the major mechanism mediating brain manganese uptake. Neurotoxicology 2004;25:451-460.
17. Moos T, Morgan EH. The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J Neurochem 2004;88:233-245.
18. Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, Land W, Tsai RY, Berger UV, Sheng ZH, Rouault TA. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res 2004;1001:108-117.
19. Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease. Ann NY Acad Sci 2004;1012:14-26.
20. Taylor EM, Crowe A, Morgan EH. Transferrin and iron uptake by the brain: Effects of altered iron status. J Neurochem 1991;57:1584-1592.
21. Malecki EA, Cable EE, Isom HC, Connor JR. The lipophilic iron compound TMH-ferrocene [(3,5,5-trimethylhexanoyl)ferrocene] increases iron concentrations, neuronal L-ferritin, and heme oxygenase in brains of BALB/c mice. Biol Trace Elem Res 2002;86:73-84.
22. Ward RJ, Dexter D, Florence A, Aouad F, Hider R, Jenner P, Crichton RR. Brain iron in the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism. Biochem Pharmacol 1995;49:1821-1826.
23. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K. Hepatocellular carcinoma caused by iron overload: A possible mechanism of direct hepatocarcinogenicity. Toxicology 2006;219:41-52.
24. Moos T, Morgan EH. Restricted transport of antitransferrin receptor antibody (OX26) through the bloodbrain barrier in the rat. J Neurochem 2001;79:119-129.
25. Delgado Zamarreno MM, Sanchez Perez A, Gomez Perez C, Hernandez Mendez J. High-performance liquid chromatography with electrochemical detection for the simultaneous determination of vitamin A, D3 and E in milk. J Chromatogr 1992;623:69-74.
26. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976;74:214-226.
27. Lykkesfeldt J. Determination of malondialdehyde dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: Comparison with UV-visible spectrophotometry. Clin Chem 2001;47:1725-1728.
28. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998;70:1781-1792.
29. Cable EE, Isom HC. Metabolism of 3,5,5-trimethylhexanoyl-ferrocene by rat liver: Release of iron from 3,5,5-trimethylhexanoyl-ferrocene by a microsomal, phenobarbital-inducible cytochrome P-450. Drug Metab Dispos 1999;27:255-260.
30. Ward RJ, Florence AL, Baldwin D, Abiaka C, Roland F, Ramsey MH, Dickson DP, Peters TJ, Crichton RR. Biochemical and biophysical investigations of the ferrocene-iron-loaded rat. An animal model of primary haemochromatosis. Eur J Biochem 1991;202:405-410.
31. Dexter DT, Ward RJ, Florence A, Jenner P, Crichton RR. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. Biochem Pharmacol 1999;58:151-155.
32. Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, Ghosh MC, McConnell JP, Rouault TA. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 2005;106:1084-1091.
33. Jeong SY, David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 2006;26:9810-9819.
34. Choi JH, Kim DW, Yu B. Modulation of age-related alterations of iron ferritin and lipid peroxidation in rat brain synaptosomes. J Nutr Health Aging 1998;2:133-137.
35. Cook CI, Yu BP. Iron accumulation in aging: Modulation by dietary restriction. Mech Ageing Dev 1998;102:1-13.
36. Florence A, Ward RJ, Peters TJ, Crichton RR. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat. Biochem Pharmacol 1992;44:1023-1027.
37. Whittaker P, Chanderbhan R, Calvert R, Dunkel V. Cellular and molecular responses in the Sprague-Dawley rat to chronic iron overload. J Trace Elem Exp Med 1994;7:19-31.
38. Nielsen P, Heinrich HC. Metabolism of iron from (3,5,5-trimethylhexanoyl) ferrocene in rats. A dietary model for severe iron overload. Biochem Pharmacol 1993;45:385-391.
39. Lambrecht RW, Cable JW, Pepe JA, Bonkovsky HL. 3,5,5- Trimethylhexanoylferrocene induction of heme oxygenase activity in normal hepatocytes. Biochem Pharmacol 1994;47:1669-1676.